Market Overview: Breast Cancer   29-page PDF document
$299.00

Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Log in to unlock full preview.
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Market Overview: Breast Cancer (29-page PDF document) Preview Image
Arrow   Click main image to view in full screen.

Market Overview: Breast Cancer (PDF)

PDF document 29 Pages

$299.00

Add to Cart
  


Immediate download
Editable with PDF editor
Free lifetime updates

BENEFITS OF DOCUMENT

  1. The breast cancer therapy market was the largest in oncology across the major markets
  2. Etiology and Pathophysiology
  3. Key Pathways and Drug Targets

DESCRIPTION

This product (Market Overview: Breast Cancer) is a 29-page PDF document, which you can download immediately upon purchase.

The breast cancer therapy market was the largest in oncology across the major markets (United States, France, Germany, Italy, Spain, United Kingdom, and Japan) in 2015 with sales of $13.8 billion. Sales are set to soar throughout our forecast period to $30.5 billion by 2025, driven by uptake of both current and emerging agents in multiple treatment settings. Two drug classes, HER2-targeted agents and CDK4/6 inhibitors, will account for over 60% of sales in this market in 2025.

Currently approved therapies will continue to have a meaningful impact on the breast cancer treatment algorithm and market sales. Pfizer's CDK4/6 inhibitor Ibrance will experience increasing use in the HR-positive, HER2-negative population, fueling this agent's sales to exceed $8.5 billion at its peak. Roche/Genentech/Chugai's HER2-targeted MAb, Perjeta, will continue to gain traction in the market, with its forecast adjuvant approval bolstering sales to exceed $5 billion in 2025.

Introduction
Key Findings
Market Share of Cancer Drug Classes in 2015 and 2025
Market SWOT Analysis
Etiology and Pathophysiology
Key Findings
Expert Insight
Pathophysiology
Anatomy
Subtypes
Staging and Classification
Key Pathways and Drug Targets
Market Outlook
Key Findings
Expert Insight
Market Overview
Market Drivers and Constraints
What Factors Are Driving the Market?
What Factors Are Constraining the Market?

Got a question about the product? Email us at support@flevy.com or ask the author directly by using the "Ask the Author a Question" form. If you cannot view the preview above this document description, go here to view the large preview instead.

Source: Best Practices in Healthcare, Cancer PDF: Market Overview: Breast Cancer PDF (PDF) Document, pharmzolgas


$299.00

Add to Cart
  

ABOUT THE AUTHOR

Author: pharmzolgas
Additional documents from author: 3

Ask the Author a Question

Must be logged in

Did you know?
The average daily rate of a McKinsey consultant is $6,625 (not including expenses). The average price of a Flevy document is $65.




Trusted by over 10,000+ Client Organizations
Since 2012, we have provided best practices to over 10,000 businesses and organizations of all sizes, from startups and small businesses to the Fortune 100, in over 130 countries.
AT&T GE Cisco Intel IBM Coke Dell Toyota HP Nike Samsung Microsoft Astrazeneca JP Morgan KPMG Walgreens Walmart 3M Kaiser Oracle SAP Google E&Y Volvo Bosch Merck Fedex Shell Amgen Eli Lilly Roche AIG Abbott Amazon PwC T-Mobile Broadcom Bayer Pearson Titleist ConEd Pfizer NTT Data Schwab




Read Customer Testimonials

 
"FlevyPro provides business frameworks from many of the global giants in management consulting that allow you to provide best in class solutions for your clients."

– David Harris, Managing Director at Futures Strategy
 
"One of the great discoveries that I have made for my business is the Flevy library of training materials.

As a Lean Transformation Expert, I am always making presentations to clients on a variety of topics: Training, Transformation, Total Productive Maintenance, Culture, Coaching, Tools, Leadership Behavior, etc. Flevy "

– Ed Kemmerling, Senior Lean Transformation Expert at PMG
 
"[Flevy] produces some great work that has been/continues to be of immense help not only to myself, but as I seek to provide professional services to my clients, it gives me a large "tool box" of resources that are critical to provide them with the quality of service and outcomes they are expecting."

– Royston Knowles, Executive with 50+ Years of Board Level Experience
 
"As a young consulting firm, requests for input from clients vary and it's sometimes impossible to provide expert solutions across a broad spectrum of requirements. That was before I discovered Flevy.com.

Through subscription to this invaluable site of a plethora of topics that are key and crucial to consulting, I "

– Nishi Singh, Strategist and MD at NSP Consultants
 
"Last Sunday morning, I was diligently working on an important presentation for a client and found myself in need of additional content and suitable templates for various types of graphics. Flevy.com proved to be a treasure trove for both content and design at a reasonable price, considering the time I "

– M. E., Chief Commercial Officer, International Logistics Service Provider
 
"I have used Flevy services for a number of years and have never, ever been disappointed. As a matter of fact, David and his team continue, time after time, to impress me with their willingness to assist and in the real sense of the word. I have concluded in fact "

– Roberto Pelliccia, Senior Executive in International Hospitality
 
"As a consultant requiring up to date and professional material that will be of value and use to my clients, I find Flevy a very reliable resource.

The variety and quality of material available through Flevy offers a very useful and commanding source for information. Using Flevy saves me time, enhances my expertise and ends up being a good decision."

– Dennis Gershowitz, Principal at DG Associates
 
"I like your product. I'm frequently designing PowerPoint presentations for my company and your product has given me so many great ideas on the use of charts, layouts, tools, and frameworks. I really think the templates are a valuable asset to the job."

– Roberto Fuentes Martinez, Senior Executive Director at Technology Transformation Advisory


Your Recently Viewed Documents


Customers Also Like These Documents

Related Management Topics


Healthcare Cancer Value Chain Analysis Integrated Financial Model

Download our FREE Strategy & Transformation Framework Templates

Download our free compilation of 50+ Strategy & Transformation slides and templates. Frameworks include McKinsey 7-S Strategy Model, Balanced Scorecard, Disruptive Innovation, BCG Experience Curve, and many more.